Methods of treating autoimmune diseases using IL-21

Details Methods of treating autoimmune diseases using IL-21 Methods of treating autoimmune diseases using IL-21

2007-10-02

2007-10-02

Nickol, Gary (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S085200

Reexamination Certificate

active

10951239

ABSTRACT:
Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical compositions can include IL-21 polypeptides and active fragments thereof.

REFERENCES:
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6605272 (2003-08-01), Novak et al.
patent: 6686178 (2004-02-01), Novak et al.
patent: 2004/0016010 (2004-01-01), Carter et al.
patent: 2004/0136954 (2004-07-01), Grusby et al.
patent: 2005/0193434 (2005-09-01), Leonard et al.
patent: 2006/0024268 (2006-02-01), Kasaian et al.
patent: 2006/0057123 (2006-03-01), Ettinger al.
patent: 2006/0159655 (2006-07-01), Collins et al.
patent: 2006/0177421 (2006-08-01), Niels et al.
patent: 2005/067956 (2005-01-01), None
James A. Wells, Sep. 18, 1990, Biochemistry, vol. 29, No. 37, pp. 8509-8517.
Mehta et al. Immunological Reviews, 2004. vol. 202, pp. 84-95.
U.S. Appl. No. 10/456,780, filed Jun. 6, 2003, Nelson et al.
U.S. Appl. No. 10/735,149, filed Dec. 12, 2003, Zamost et al.
U.S. Appl. No. 11/539,036, filed Oct. 5, 2006, Zamost et al.
U.S. Appl. No. 11/539,045, filed Oct. 5, 2006, Zamost et al.
U.S. Appl. No. 11/539,055, filed Oct. 5, 2006, Zamost et al.
U.S. Appl. No. 10/456,262, filed Jun. 6, 2003, Nelson et al.
U.S. Appl. No. 11/553,367, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,381, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,389, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,392, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,395, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/548,196, filed Oct. 10, 2006, Nelson et al.
U.S. Appl. No. 11/548,202, filed Oct. 10, 2006, Nelson et al.
U.S. Appl. No. 11/548,517, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,530, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,538, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,554, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,567, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,574, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,585, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,877, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/548,946, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/548,963, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/548,969, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/539,479, filed Oct. 6, 2006, Kindsvogel et al.
U.S. Appl. No. 11/539,493, filed Oct. 6, 2006, Kindsvogel et al.
U.S. Appl. No. 11/539,511, filed Oct. 6, 2006, Kindsvogel et al.
U.S. Appl. No. 11/285,970, filed Nov. 23, 2005, Yee.
U.S. Appl. No. 10/659,684, filed Sep. 10, 2003, Novak et al.
U.S. Appl. No. 11/549,772, filed Oct. 16, 2006, Novak et al.
U.S. Appl. No. 11/551,807, filed Oct. 23, 2006, Novak et al.
U.S. Appl. No. 11/551,344, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/549,868, filed Oct. 16, 2006, Novak et al.
U.S. Appl. No. 11/551,356, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/551,362, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/551,368, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/551,811, filed Oct. 23, 2006, Novak et al.
U.S. Appl. No. 11/551,820, filed Oct. 23, 2006, Novak et al.
U.S. Appl. No. 10/787,442, filed Feb. 26, 2004, Novak et al.
U.S. Appl. No. 11/532,776, filed Sep. 18, 2006, Novak et al.
U.S. Appl. No. 11/551,127, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,136, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,139, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,144, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,349, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/563,928, filed Nov. 28, 2006, Sivakumar et al.
U.S. Appl. No. 11/564,001, filed Nov. 28, 2006, Sivakumar et al.
U.S. Appl. No. 11/346,580, filed Feb. 2, 2006, Novak et al.
O'Shea et al., “A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway,”Nat Rev Drug Discov. 3(7):555-64, 2004.
Pene et al., “Cutting Edge: IL-21 is a Switch Factor for the production of IgG1and IgG3by Human B Cells,”J. Immunol. 172(9):5144-7, 2004.
Jungel et al., “Expression of Interleukin-21 Receptor, but Not Interleukin-21, in Synovial Fibroblasts and Synovial Macrophages of Patients withRheumatoid Arthritis,”Arthritis Rheum. 50(5):1468-76, 2004.
Ozaki et al., “Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6,”J Immunol. 173(9):5361-71, 2004.
Gallegos et al., “Driven to Autoimmunity: the Nod Mouse,”Cell 117(2):149-51, 2004.
Monteleone et al., “IL-21 enhances TH1 cell signaling and INF gamma production in Crohn's disease,”Gastroenterol 126(4):, 2004.
O'Shea et al., “Jak3 and the pathogenesis of severe combined immunodeficiency,”Mol Immunol. 727-37, 2004.
Sivakumar et al., Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumor responses,:Immunology 112(2):177-82, 2004.
Distler et al., “Overexpression of IL-21 Receptor mRNA in the Epidermis of Patients with Systemic Sclerosis: Lessons from the SCID Mouse Transplantation Model,”Ann. Rheumatic Diseases 63(S1): OP0158, 2004.
Rowshani et al., “Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro,”Eur J Immunol. 34(3):882-99, 2004.
Asli et al., “Roles of lymphoid cells in the differentiation of Langerhans dendritic cells in mice,”Immunobiology 209(1-2):209-21, 2004.
Sague et al., “The Presence of IL-21 During Differentiation of Bone Marrow-Derived Dendritic Cells Inhibits Dendritic Cell Maturation,”J. Leukocyte Biol. Supp(0):162, 2004.
Alexopoulos et al., “Tolerance Induction Using IL-21 Antagonizing Fusion Protein,”Experimental Tolerance Induction Conf. 09(0): Abs. 101, 2004.
Brandt et al. “Interleukin-21 Inhibits Dendritic Cell-Mediated T Cell Activation and Induction of Contact Hpersensitivity In Vivo,”J. Invest. Dermatol 121(6):1379-82, 2003.
Brandt et al., “Interleukin-21 inhibits dendritic cell activation and maturation,”Blood 102(12):4090-8, 2003.
Distler et al., “Inflammation-independent Overexpression of IL-21 Receptor in mRNA in Keratinocytes from Patients with Systemic Sclerosis,”Am. College of Rheumatol. Abs. Suppl. Abst. 848, 2003.
Cohen et al., “Increased expression of CD132 and multiple IL-2 family receptors in psoriasis vulgaris,”J. Investigative Dermatol. Abst. 0115, 2003.
Cui et al. “Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice,” Ueda et al., “Expression of Functional IL-21 Receptor on adult T-cell Leukemia Cells,”Blood 102(11), 2003.
Suto et al., “Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4-stimulated B cells,”Blood 100(13):4565-73, 2002.
De Groot-Kruseman et al., “Expression of the Novel Cytokine IL-21 During Acute Rejection After Clinical Heart Transplantation and the Effect of Immunosuppressive Agents,”J. Interferon Cytokine Res. 22(S1): abst. P-2-1, 2002.
Witek et al., “Primary Machrophages Express IL-21R and Respond to IL-21 by Proliferating and Secreting Increased Levels of Cytokines and Chemokines,” abst. P-2-12, 2002.
Keane-Myers et al., “A Role for IL-21 in Mouse Models of Allergic Asthma,” Keystone Symposia, Cytokines, Disease and Therapeutic Intervention, 2005.

Affiliated with

Also associated with

Rating

Methods of treating autoimmune diseases using IL-21 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating autoimmune diseases using IL-21, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating autoimmune diseases using IL-21 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3852689